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Abstract
Purpose Recently, a GGGGCC hexanucleotide repeat expan-
sion in the C9ORF72 gene, located on chromosome 9p21 has
been demonstrated to be the commonest cause of familial
amyotrophic lateral sclerosis (ALS) and to account for 5 to
10 % of apparently sporadic ALS. Relatively little is known
about the brain metabolism profile of patients carrying the
expansion. Our aim was to identify the [18F]FDG PET
profile in ALS patients with the C9ORF72 expansion
(C9ORF72-ALS).
Methods Fifteen C9ORF72-ALS patients were compared
with 12 patients with ALS and comorbid frontotemporal
dementia (FTD) without the C9ORF72 expansion (ALS-
FTD) and 30 cognitively normal patients with ALS without
mutations of ALS-related genes (sALS). The three groups
were then cross-matched to 40 neurologically normal controls.
All patients underwent FDG PET within 4 months of
diagnosis.
Results The C9ORF72-ALS patients compared with the
sALS patients showed significant hypometabolism in the
anterior and posterior cingulate cortex, insula, caudate and
thalamus, the left frontal and superior temporal cortex, and
hypermetabolism in the midbrain, bilateral occipital cortex,
globus pallidus and left inferior temporal cortex. The ALS-
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FTD patients compared with the sALS patients showed more
limited hypometabolic areas, including the orbitofrontal, pre-
frontal, anterior cingulate and insular cortex, and hypermeta-
bolic areas, including the bilateral occipital cortex, the left
precentral and postcentral cortex and superior temporal gyrus.
The C9ORF72-ALS patients compared with the ALS-FTD
patients showed hypometabolism in the left temporal cortex.
Conclusion ALS patients with the C9ORF72 hexanucleotide
repeat expansion had a more widespread central nervous
system involvement than ALS patients without genetic muta-
tions, with or without comorbid FTD, consistent with their
more severe clinical picture.
Keywords Amyotrophic lateral sclerosis .C9ORF72gene .
FDGPET
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder characterized by loss of cortical, bulbar and spinal
motor neurons, leading to progressive palsy of voluntary
muscles and ultimately death due to respiratory failure, usu-
ally within 3 years of onset [1]. While the majority of cases
appears sporadically in the population, 10% of patients have a
positive family history of ALS or frontotemporal dementia
(ALS-FTD), a related form of neurodegeneration [2, 3]. Re-
cently, our group and others have demonstrated that a GGGG
CC hexanucleotide repeat expansion in the C9ORF72 gene
located on chromosome 9p21 is the commonest cause of
familial ALS and also accounts for up to 10 % of apparently
sporadic ALS [3–7]. Patients with this C9ORF72
hexanucleotide repeat expansion are characterized clinically
by an overlap phenotype consisting of ALS and FTD, some-
times including extrapyramidal and psychiatric signs (mainly
delusions and hallucinations) [2, 3].
Relatively little is known about the anatomofunctional
profile of patients carrying the pathogenetic expansion, espe-
cially those presenting with motor neuron dysfunction. Sym-
metric bilateral frontal and temporal cortical atrophy has been
demonstrated using MRI in a cohort of 18 FTD or ALS-FTD
patients carrying the pathogenetic expansion [8]. Magnetic
resonance grey-matter voxel-based morphometry identified
significant grey-matter atrophy in the right inferior and supe-
rior frontal gyrus, left anterior cingulate gyrus, and right
precentral gyrus in four patients with FTD [2] and in ten
patients with ALS-FTD carrying the pathogenetic expansion
[9]. A PET study involving five patients with the C9ORF72
expansion presenting with a FTD phenotype revealed glucose
hypometabolism in the frontal cortex and the anterior cingu-
late gyrus compared with an age-segmented normative data-
base [9]. However, to date, there have been no studies exam-
ining the functional characteristics of ALS patients with the
C9ORF72 hexanucleotide repeat expansion compared with
both ALS patients without the mutation and controls.
The aim of our study was to address this gap in our
knowledge by performing brain [18F]FDG PET in a series of
ALS patients with the C9ORF72 hexanucleotide repeat ex-
pansion and to compare their scans with those of ALS-FTD
and cognitively normal ALS patients without mutations of
C9ORF72 or other ALS-related genes.
Methods
Patients and controls
A series of 195 ALS patients with probable, probable
laboratory-supported or definite ALS according to the revised
criteria of El Escorial [10], consecutively seen at the Turin
ALS centre, participated in a cross-sectional study with FDG
PET. Patients underwent PET within 4 months of diagnosis.
Among these patients, we identified three groups: (1) 15
patients carrying the C9ORF72 expansion (C9ORF72-ALS),
(2) 12 ALS patients with comorbid FTD who did not carry the
expansion or any known ALS-related genetic mutation (ALS-
FTD), and (3) 30 cognitively normal ALS patients who did
not carry the expansion or any known ALS-related genetic
mutation (sALS) and who were matched for age, gender,
disease duration, and clinical phenotype to the C9ORF72-
ALS patients.
Each group was compared with a neurologically normal
control cohort consisting of 40 subjects who underwent 18F-
FDG PET scanning and found to be negative for neoplastic
diseases. Exclusion criteria for both ALS patients and control
subjects were: the presence of major systemic illness, major
vision disturbances, psychiatric illnesses, epilepsy, head trau-
ma, parkinsonism, previous stroke or transitory ischaemic
attack, brain masses, and current use of benzodiazepines or
tricyclic antidepressants.
Genetic analysis
A repeat-primed PCR assay was used to screen for the pres-
ence of the GGGGCC hexanucleotide expansion in the first
intron of C9ORF72 [6]. A repeat expansion of ≥30 was
considered to be pathological. All patients were also screened
for mutations in genes more commonly implicated in ALS in
Caucasian populations, namely SOD1, FUS, TARDBP, OPTN
and ANG [11].
Cognitive evaluation
FTD diagnosis was defined according to the criteria of Neary
et al. [12]. ALS patients and controls underwent a detailed
neuropsychological test battery [13] and were classified as
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having FTD, as having isolated executive impairment, or as
being cognitively normal [14]. The following tests were ap-
plied: Frontal Systems Behavior Scale, using the Family form
evaluated by a close relative (scores: normal ≤59, borderline
60 – 64; pathological ≥65) [15]; Mini Mental State Examina-
tion; Wisconsin Card Sorting Test; Trail Making A and B;
Stroop Colour-Word Interference Test; letter and category
fluency test; Wechsler Memory Scale–revised; Rey-
Osterrieth Complex Figure Test; Token test; Wechsler Adult
Intelligence Scale revised; and Raven’s Progressive Coloured
Matrices. Depression and anxiety were evaluated with the
Hospital Anxiety and Depression Scale.
18F-FDG PET imaging
Subjects fasted for at least 6 h prior to imaging. Before
radiopharmaceutical injection, blood glucose was measured
(<7.2 mmol/l in all cases). According to EANM guidelines
[16] after a 20-min rest period in a silent and darkened room,
with eyes closed and ears unplugged, subjects were injected
with approximately 185 MBq of 18F-FDG through an intra-
venous cannula. PET/CT scanning was started approximately
40 min after injection and lasted another 10 min. A polycar-
bonate head holder was applied to reduce head movements
during the scan.
The PET/CT scans were acquired using a Discovery ST-E
System (General Electrics Medical Systems, Milwaukee, WI)
with an axial resolution of 5.2 mm FWHM in three-
dimensional mode. FDG PET/CT images were acquired in
three dimensions as two sequential scans: a brain CT scan
(thickness 3.75 mm, 140 kV, 60 – 80 mA) and a brain PET
scan (one field of view of 30 transaxial centimetres). The PET
scan was started immediately after the CT scan in order to use
the CT data for attenuation correction of the PET data. Scatter
correction was performed using the three-dimensional recon-
struction algorithm. Data were collected in 128×128 matrices
with reconstructed voxels of 2.34×2.34×2.00 mm.
Statistical analysis
A two-sample unpaired t-test was used to differentiate groups
based on age and executive tests scores, while the chi-squared
test was used to evaluate differences in gender distribution.
Analyses were performed using age, gender and type of onset
(bulbar vs. spinal) as covariates.
Using SPM2 (Wellcome Department of Cognitive Neurol-
ogy, London, UK) implemented in Matlab 6.5 (Mathworks,
Natick, MA), PET data were subjected to affine and nonlinear
spatial normalization into MNI space. The spatially normal-
ized set of images was then smoothed using an 8-mm isotropic
gaussian filter to blur individual variations in gyral anatomy
and to increase the signal-to-noise ratio. The resulting statis-
tical parametric maps, SPM{t}, were transformed into normal
distribution (SPM{z}) units. The SPM coordinates were
corrected to match the Talairach coordinates by the subrou-
tine implemented by Matthew Brett (http://brainmap.org/
index.html). Brodmann areas (BAs) were then identified at
a range of 0 to 3 mm from the corrected Talairach coordi-
nates of the SPM output isocentres, after importing the
corrected coordinates, by Talairach client (http://www.
talairach.org/index.html).
In order to test the overall statistical significance of meta-
bolic differences, one-way analysis of variance (ANOVA)was
performed using the SPM2 f-contrast routine using all four
groups as factors. Subsequently multiple unpaired t-tests be-
tween the four groups were performed using the “compare
population: one-scan per subject” routine.
We used a pvalue threshold of <0.05 corrected for multiple
comparisons with the False Discovery Rate (FDR) option, to
explore SPM t-maps at the voxel level [6]. If statistical signif-
icance was not reached the threshold at the voxel level was
explored at p<0.001 uncorrected for multiple comparisons.
This more liberal choice can be adopted to avoid type II errors
attributable to over-conservative thresholds [17]. Given the
exploratory nature of this analysis and considering the rela-
tively low sensitivity of PET without repeated measures,
higher thresholds could lead to false-negative results in PET
studies.
The significance of the identified area was established at a p
value of <0.05 corrected for multiple comparisons at the
cluster level. Only clusters containing more than 125 voxels
were considered to be significant based on the calculation of
the partial volume effect (PVE) resulting from the spatial
resolution of the PET camera (about double the FWHM).
Standard protocol approval and patient consent
The study design was approved by the institutional ethics
committee. Patients and caregivers provided written informed
consent.
Results
Demographics and clinical characteristics of the C9ORF72-
ALS, the sALS and the ALS-FTD patients, and the neuro-
logically normal controls are presented in Table 1. The three
groups of ALS patients were fully comparable, with the
obvious exception of FTD comorbidity. A detailed descrip-
tion of the C9ORF72-ALS patients is provided in the sup-
plementary data (Table E-1). No ALS-FTD patients showed
hallucinations or delusions and none had a positive family
history of ALS or FTD. Cognitive test findings are presented
in Table E-2.
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PET findings
One-way ANOVA showed a highly significant overall differ-
ence (p<0.05 FDRcorrected) among the groups.
C9ORF72-ALS vs. sALS. C9ORF72-ALS patients showed
highly significant (p<0.05 FDRcorrected) relative hypometabolism
in the bilateral anterior and posterior cingulate cortex (BAs 23
and 24), insula (BA 13), caudate and thalamus, and the left
frontal (BA 8) and superior temporal (BAs 22 and 38) cortices
(Fig. 1a; Table E-3, Fig. E-1). There was also relative hyperme-
tabolism (p<0.05 FDRcorrected) in the C9ORF72-ALS patients in
the midbrain, bilateral occipital cortex (BAs 17, 18 and 19),
globus pallidus and the left middle (BA 39) and inferior temporal
(BA 37) cortices (Fig. 1b; Table E-3, Fig. E-2).
ALS-FTD vs. sALS. ALS-FTD patients showed relative
hypometabolism (p<0.001) in the right orbitofrontal (BAs
11 and 47), prefrontal (BAs 9 and 10), anterior cingulate
(BA 32) and insular (BA 13) cortices (Fig. 2a; Table E-4,
Fig. E-3). There was also relative hypermetabolism (p<0.001)
in ALS-FTD patients in the bilateral occipital (BAs 17, 18 and
19) cortex, in the left precentral and postcentral (BAs 6 and
43) cortices, and the superior temporal gyrus (BA 42) (Fig. 2b,
Table E-4, Fig. E-4).
C9ORF72-ALS vs. ALS-FTD. C9ORF72-ALS patients
showed relative hypometabolism (p<0.001) in the left tempo-
ral cortex (BA 22) (Fig. 3; Table E-5, Fig. E-5). No significant
hypermetabolism was found in this comparison.
Patients vs. controls. C9ORF72-ALS patients showed a large
hypometabolic area (p<0.05 FDRcorrected) in the bilateral cau-
date and the thalamus as well as in the frontal cortex (BAs 6, 8,
9, 10, 32, 44, 45, 46) and insula (BA 13) (Fig. E-6, Table E-6).
The same pattern (p<0.001) was seen in ALS-FTD patients in
Table 1 Clinical characteristics of the C9ORF72-ALS, the sALS and the ALS-FTD patients, and the neurologically normal controls
C9ORF72-ALS (n=15) sALS (n=30) ALS-FTD (n=12) Controls (n=40) p valuea
Age at onset (years), mean (SD) 58.6 (10.2) 58.2 (10.6) 64.8 (9.1) 62.2 (14.1) n.s.
Gender (women), n (%) 4 (26.7 %) 13 (43.3 %) 6 (50 %) 14 (35 %) n.s.
Site of onset (bulbar), n (%) 7 (46.7 %) 13 (43.3 %) 6 (50 %) – n.s.
Disease duration at time of PET (months), mean (SD) 10.1 (7.3) 12.1 (8.8) 12.1 (8.6) – n.s.
ALSFRS-R score at time of PET, mean (SD) 41.2 (4.5) 42.3 (5.1) 41.7 (4.9) – n.s.
FTD, n (%) 10 (66.7 %) 0 12 (100 %) 0 –
Isolated executive dysfunction, n (%) 2 (13.3 %) 0 0 0 –
a Patient and control groups were compared with ANOVA
Fig. 1 PET findings in 15 C9ORF72-ALS patients compared with 30
sALS patients. Statistically significant differences (p<0.05 FDR) are
highlighted on a MRI T1 template. a Hypometabolism: top left sagittal
view, top right coronal view. bottom left transverse view. Significant
corrected clusters are seen in the bilateral anterior and posterior cingulate
cortex, insula, caudate and thalamus, and the left frontal and superior
temporal cortices. b Hypermetabolism: top left sagittal view, top right
coronal view, bottom left transverse view. Significant corrected clusters
are seen in themidbrain, bilateral occipital cortex, the globus pallidus, and
the left middle and inferior temporal cortices
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that a hypometabolic area covered part of both frontal cortices
(BAs 6, 8, 9, 44, 45, 47), though not as extensively as observed
in the C9ORF72-ALS patients (Fig. E-8, Table E-7).
C9ORF72-ALS patients showed hypermetabolism (p<0.05
FDRcorrected) in the midbrain and the cerebellum, in several
bilateral limbic regions (hippocampus, amygdale, insula and
temporal pole) (Fig. E-7, Table E-5). In contrast, ALS-FTD
patients only exhibited increased relative metabolism in the left
cerebellum and midbrain (p<0.001) (Fig. E-9, Table E-6).
sALS patients showed a largely diffuse relative
hypometabolism (p<0.05 FDRcorrected) in the bilateral
occipitotemporoparietal and parietofrontal cortices, and hy-
permetabolism (p<0.001) in the medial-superior temporal
lobe (BAs 28 and 38, and hippocampus) (Figs. E-10 and E-
11, Table E-7) as compared with non-ALS controls.
Discussion
We compared the glucose metabolism distribution in a series
of 15 ALS patients carrying the GGGGCC hexanucleotide
repeat expansion of the C9ORF72 gene, 30 cognitively nor-
mal ALS patients, 12 ALS-FTD patients and 40 non-ALS
controls. Investigating neurodegenerative disorders by FDG
PET contributes to the elucidation of their neurobiology by
defining specific metabolic patterns for potential diagnostic
use. Along with structural investigations, functional studies
provide complementary information about disease’s staging
and progress resulting in a better clinical characterization. This
is being progressively achieved in, for example, Alzheimer’s
Disease and mild cognitive impairment, in which FDG PET
investigations provide reliable discriminations between the
two groups of patients as well as between patients and controls
[18, 19].
In the present study a defined metabolic pattern of a genet-
ically well-defined subgroup of ALS patients was found,
encouraging the use of FDG PET in the clinical screening
algorithm of this devastating neurodegenerative disorder. The
Fig. 2 PET findings in 12 ALS-FTD patients compared with 30 sALS
patients. Statistically significant differences (p<0.001) are highlighted on
a MRI T1 template. a Hypometabolism: top left sagittal view, top right
coronal view, bottom left transverse view. Significant corrected clusters
are seen in the right orbitofrontal, prefrontal, anterior cingulate and insular
cortices. bHypermetabolism: top left sagittal view, top rightcoronal view,
bottom left transverse view. Significant corrected clusters are seen in the
bilateral occipital cortex, in the left precentral and postcentral cortex and
the superior temporal gyrus
Fig. 3 PET findings in 15 C9ORF72-ALS patients compared with 12
ALS-FTD patients. Statistically significant differences (p<0.001) are
highlighted on a MRI T1 template. Hypometabolism: top left sagittal
view, top right coronal view, bottom left transverse view. Significant
corrected clusters are seen in the left temporal cortex. No significant
hypermetabolism was found in this comparison
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C9ORF72-ALS patients had a unique distribution of metabol-
ic activity when compared with the sALS patients, with rela-
tive hypometabolism in several areas of the limbic system
(posterior and anterior cingulate cortex, insula, and temporal
pole) and of the central structures (caudate and thalamus),
while in the ALS-FTD patients less severe hypometabolism
was limited to smaller areas of the insula and orbitofrontal,
prefrontal and anterior cingulate cortices. As compared with
the sALS patients, both the C9ORF72-ALS and ALS-FTD
patients showed hypermetabolism in the occipital cortex
which was more severe in the C9ORF72-ALS patients, that
also showed significant hypermetabolism in the midbrain.
When compared with the ALS-FTD patients, C9ORF72-
ALS patients showed hypometabolism in the left temporal
cortex. Temporal atrophy has previously been found in ALS-
FTD patients [8] and might be exacerbated in C9ORF72-ALS
patients accounting for the relative hypometabolism found in
these patients.
We did not find a difference in the midbrain between the
C9ORF72-ALS patients and ALS-FTD patients, possibly due
to the relatively low number of subjects in the two groups that
might have resulted in a subthreshold trend not reaching
statistical significance. However, a previous study has shown
different degrees of midbrain hypermetabolism in ALS patient
subgroups [20], and this finding was confirmed in the present
study in C9ORF72-ALS patients as compared with normal
controls, underscoring its distinctive role as a biomarker in the
most severe cases of ALS [21].
Although the C9ORF72 expansion has only recently been
described, a pattern is beginning to emerge in terms of imaging
characteristics in these patients. In accordance with our results,
PET scanning involving five C9ORF72 carriers presenting
with a FTD phenotype showed hypometabolism in the anterior
cingulate, with mild to severe frontal cortical hypometabolism
[8]; the anterior cingulate dysfunction was confirmed using
perfusion single photon emission tomography [8].
Specific patterns of cortical and regional central nervous
system (CNS) atrophy have also been described in C9ORF72-
ALS patients based on MRI. Symmetric bilateral frontal and/
or temporal cortical atrophy, associated with ventricular en-
largement in serial scans, is a common finding in C9ORF72-
ALS patients with a predominant FTD phenotype [8, 21].
Voxel-based morphometry analysis showed clusters of grey
matter cortical atrophy in the right inferior and superior frontal
gyri, the left anterior cingulate gyrus, and the right precentral
gyrus in ALS and ALS-FTD patients withC9ORF72mutation
[2]. In contrast, similar analyses in FTD patients with the
expansion revealed atrophy involving the bilateral thalamus,
left opercular cortex, left orbitofrontal cortex and bilateral
posterior cerebellum [22]. Diffusion tensor imaging analysis
of FTD and ALS-FTD patients with the C9ORF72mutation
showed increased radial diffusivity and decreased fractional
anisotropy bilaterally in the anterior thalamic radiations,
uncinate fasciculus, anterior cingulum, anterior corpus
callosum, right posterior corpus callosum, posterior inferior
longitudinal fasciculus and superior longitudinal fasciculus
[22]. A recent study in nine ALS patients with a C9ORF72
genotype showed anatomic involvement of cortical and sub-
cortical regions, affecting fusiform, thalamic, supramarginal,
orbitofrontal regions and Broca’s area [23].
Our study provides important novel information
concerning PET imaging in C9ORF72 patients presenting
with ALS. Such patients have a different pattern of impaired
metabolism as compared with ALS patients without genetic
mutations, either cognitively normal or with comorbid FTD.
Hypometabolism involved specifically the limbic system and
the central structures, while hypermetabolism was found in
the midbrain. These changes were independent of site of
onset, age and gender. We were able to identify this unique
metabolic pattern in patients with the C9ORF72 expansion
even though the number of patients included in the study,
although much larger than in any other published study, was
still relatively small.
These diffuse, highly significant and quite complex meta-
bolic changes differentiate ALS patients with the C9ORF72
expansion from those without genetic mutations and from
normal controls. The widespread CNS involvement observed
in the PET scan is consistent with the more severe clinical
picture observed among patients carrying the expansion [3], as
well as with the findings of post-mortem studies showing
more extensive neuropathological changes compared with
ALS patients without the mutation [24, 25]. Of our 15
C9ORF72-ALS patients, 10 had a comorbid behavioural var-
iant FTD, sometimes characterized by florid psychosis-like
symptoms, while two patients had an isolated executive im-
pairment and only three were cognitively normal. Interesting-
ly, in our series of ALS patients with this mutation, several
patients’ relatives showed FTD comorbid with psychotic
symptoms or frank schizophrenia [2, 3, 7].
The hypometabolism of the bilateral frontal cortex found
in the C9ORF72-ALS patients in comparison with both the
sALS patients and the non-ALS controls is consistent with
the presence of impairment of frontal functions typically
observed in patients with FTD, and is more severe and
extended than that observed in ALS-FTD without the ex-
pansion. However, hypometabolism of the anterior and pos-
terior cingulate cortex has been related to behavioural symp-
toms, such as inability to detect errors, severe difficulty with
resolving stimulus conflict, emotional instability and inatten-
tion [26], a symptom constellation usually observed in ALS-
FTD as well as in patients with the C9ORF72 expansion
[13]. Involvement of the anterior cingulate cortex and stria-
tum has also been reported in patients with schizophrenia
[27–29], and could represent the functional correlate of
psychosis-like symptoms often those observed in ALS pa-
tients with the C9ORF72 mutation.
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Evidence of parkinsonism has been reported in about 35 %
of patients with behavioural variant FTD or ALS-FTD carry-
ing the C9ORF72 expansion, with a symmetric akinetic-rigid
syndrome and, less frequently, posture and action tremor [8].
Similar parkinsonian features have been reported in patients
with ALS or ALS-FTD with the same mutation, and parkin-
sonian syndromes are identified quite frequently in the pedi-
grees of their families [3, 25]. In the present series, three of the
C9ORF72-ALS patients (20 %) had clear-cut parkinsonian
symptoms not responsive to treatment with levodopa. The
detection of the metabolic changes in the basal ganglia is
consistent with the finding of extrapyramidal symptoms in
these patients. Additionally, the involvement of the basal
ganglia may also influence a patient’s cognition, both as a
direct effect of the impairment, and also as part of circuits
encompassing the basal ganglia and cortical structures [30],
including the anterior cingulate cortex, dorsolateral prefrontal
cortex, and supplementary motor area. In this regard, it is
interesting to note that the C9ORF72 expansion has also been
reported in patients clinically diagnosed with Alzheimer’s and
idiopathic Parkinson’s disease [31, 32], in keeping with the
widespread distribution of neuropathological defects observed
with this mutation.
Apart from typical upper and lower motor neuron loss,
pathology in ALS patients with the C9ORF72 expansion is
characterized by extensive involvement of extramotor areas,
such as the frontal cortex, temporal cortex, hippocampus,
substantia nigra, and cerebellar granule cells [8, 23–25]. Ob-
viously, neuropathological examination represents the end-
stage of the disease. However, our imaging findings were
acquired early after the clinical diagnosis, but in patients with
theC9ORF72expansion still showedmore widespread chang-
es within the CNS than patients without the mutation, indicat-
ing that pathological changes are present in those with the
C9ORF72 expansion from a relatively early stage of the
disease. Patients with the C9ORF72 mutation had relative
glucose hypermetabolism in the midbrain compared both with
controls and to cognitively normal ALS with no mutations.
This unique findingmight be related to reactive astrocytosis or
to a local increase in microglia [33, 34], and could be a
relatively specific phenomenon in ALS patients [20].
Glutamate-induced glycolysis in astrocytic syncytium pro-
vides lactate as the substrate for neuronal firing and activates
astrocytes by taking up glucose directly from intraparenchymal
capillaries [35, 36]. In vivo evidence has been found by MRI
spectroscopy that the glutamate excess in patients with ALS is
proportional to the presence of dysarthria and dysphagia [37].
When neurons degenerate such a neurometabolic loop might
cause increased 18F-FDG accumulation in ALS. Furthermore,
glycogen synthesis in the brain is almost exclusively localized
in astrocytes and is considered to be a mechanism providing
additional energy substrate upon glutamatergic stimulation. All
these phenomena may in turn result in the affected regions in
an increase in the relative uptake of 18F-FDG due to the higher
density of astrocytes and microglia in ALS patients than in
controls.
A relevant issue in neuroimaging is the correction of met-
abolic data for PVE in potentially atrophic regions. In our
study MRI scans of several patients were not available due to
the difficulty that ALS patients may experience in undergoing
an MRI scan. In fact only some of our patients could tolerate
the MRI scan, and we felt inappropriate to correct the PET
data for PVE only in a limited sample of patients. Using
segmented MR images, Ibáñez et al. [38] corrected metabolic
rates for glucose for PVE to evaluate the effect of atrophy on
uncorrected values. In that study metabolic differences were
confirmed after PVE correction and were not a mere artefact
due to an increase in the cerebrospinal fluid space induced by
the atrophy. Although neither age nor sex showed differences
among the groups, we included them as covariates in the voxel
analyses. This kept the variability under control and made the
results more stable, primarily because both of these variables
are known to have an impact on brain metabolism, irrespec-
tive of significant differences at the group level [39]
This study had some limitations. First, the use of a conve-
nience group of subjects with a negative PETscan as a control
group was suboptimal. However, these patients were specifi-
cally identified for this study and the same protocol and
scanner were used in both patients and controls. Furthermore,
as in other investigations, strict exclusion criteria were applied
and the enrolment of these patients avoided exposure of
healthy individuals to radiation [40]. Second, the finding of
hypermetabolic areas could be an artefact of global mean
normalization in the SPM procedure. However, we overcame
this issue by allowing the normalization value to incorporate
only those voxels with a value higher than the global mean
and a post-hoc crossvalidation with higher thresholds has been
performed that confirmed the present results [41].
In conclusion, we found that ALS patients with theC9ORF72
mutation are characterized by a pattern of glucose metabolism
different from that in normal subjects and ALS patients with no
genetic mutation, with relative hypometabolism in the thalamus,
basal ganglia and limbic cortex and relative hypermetabolism in
the occipital cortex, midbrain and bilateral cerebellum. These
alterations are consistent with the unique symptom constellation
in patients carrying the C9ORF72 hexanucleotide repeat expan-
sion, and emphasize the ‘systemic’ nature of lesions related to
this mutation even in the early clinical phases of the disorder.
Although the ALS subgroups were created on the basis of
genetic and cognitive data, in none of them brain metabolism
correlated significantly with any of the neuropsychological
tests. This was possibly due to the small sample size but also
to the lack of significant cognitive decline in some of the
genetically impaired patients. In this respect the ability of
18F-FDG PET to demonstrate metabolic differences between
such clinically similar patient groups might help to identify a
850 Eur J Nucl Med Mol Imaging (2014) 41:844–852
pattern unique to patients with the C9ORF72mutation useful
in the diagnostic algorithm. Larger groups of patients bearing
the same hexanucleotide repeat expansion are needed to con-
firm this hypothesis.
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